Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Active:	Yes
Cancer Type:	Solid Tumor Unknown Primary	NCT ID:	NCT04699188
Trial Phases:	Phase I Phase II	Protocol IDs:	CJDQ443A12101 (primary) NCI-2021-01594
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Novartis Pharmaceuticals Corporation
NCI Full Details:	http://clinicaltrials.gov/show/NCT04699188

Summary

This is a phase Ib/II open label study. The escalation part will characterize the safety
and tolerability of JDQ443 single agent and JDQ443 in combination with the other study
treatments (TNO155 and tislelizumab) in advanced solid tumor patients. After the
determination of the maximum tolerated dose / recommended dose for a particular treatment
arm, dose expansion will assess the anti-tumor activity and further assess the safety,
tolerability, and PK/PD of each regimen at the maximum tolerated dose / recommended dose
or lower dose.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.